Skip to main content
54°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aurinia Pharmaceuticals Inc.
< Previous
1
2
3
4
Next >
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
November 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
November 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
October 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
September 24, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
September 13, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces Board Restructuring
September 12, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
September 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
August 28, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
August 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
July 19, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
July 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces 2024 Annual General Meeting Results
June 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
June 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
June 04, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Provides Update on Proxy Statement
June 03, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
May 14, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
May 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
May 02, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
May 01, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
April 30, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
February 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.